β-1,4-Gal-T1 Antibody [C2J8]

Catalog No.: F4313

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:100-1:1000
    1:100-1:200
    1:50-1:500
    Application
    WB, IP, IHC, IF, ELISA
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    44 kDa

    Datasheet & SDS

    生物学的記述

    Specificity
    β-1,4-Gal-T1 Antibody [C2J8] detects endogenous levels of total β-1,4-Gal-T1 protein.
    Clone
    C2J8
    Synonym(s)
    Beta-1,4-galactosyltransferase 1, Beta-1,4-GalTase 1; Beta4Gal-T1; b4Gal-T1, B4GALT1, GGTB2
    Background
    β-1,4-Galactosyltransferase 1 (β-1,4-Gal-T1/B4GALT1) is a type II Golgi-resident glycosyltransferase of the β4GalT family that uses UDP-galactose to add β1,4-linked galactose onto terminal N-acetylglucosamine, glucose, or xylose residues, providing a key late elongation step in N-glycan processing and broader glycoconjugate biosynthesis, while uniquely also participating in lactose production in lactating mammary epithelium. The enzyme is synthesized as a type II membrane glycoprotein with an N‑terminal cytosolic tail, a single transmembrane anchor that serves as an uncleaved signal for Golgi targeting, a short luminal stem, and a C‑terminal catalytic domain that binds UDP‑galactose and positions acceptor sugars in a metal‑dependent active site to form Galβ1‑4GlcNAc (N‑acetyllactosamine) and related disaccharide units. B4GALT1 recognizes terminal GlcNAc in complex and hybrid N‑glycans and extends these termini with β1,4‑galactose, generating N‑acetyllactosamine repeats that are further modified by sialyltransferases nd fucosyltransferases into diverse antigenic and adhesion‑related epitopes, thereby controlling the composition of glycoprotein and glycolipid surfaces that mediate cell–cell and cell–matrix interactions. In the Golgi, the transmembrane domain and homodimerization of B4GALT1 contribute to its retention in trans‑Golgi cisternae, where it works in an ordered sequence with other glycosyltransferases, and its localization and activity are sensitive to perturbations in intra‑Golgi trafficking complexes, such as COG, which when disrupted cause mislocalization and hypogalactosylation of N‑glycans. The same gene also generates a shorter transcript that is cleaved to a soluble form that pairs with α‑lactalbumin in the mammary gland to form lactose synthase; binding of α‑lactalbumin remodels the sugar‑binding pocket, shifts the acceptor preference from GlcNAc to glucose, and converts the broad glycosyltransferase into a lactose synthase that transfers galactose from UDP‑Gal to glucose as the final step in lactose biosynthesis during lactation. Genetic defects in B4GALT1 underlie congenital disorder of glycosylation type 2D, characterized by undergalactosylated N‑glycans, multi‑system involvement, and coagulopathy, and glomerular upregulation and altered activity of B4GALT1 have been associated with IgA nephropathy, highlighting the importance of its galactosylation function in both systemic glycoprotein maturation and organ‑specific pathology.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください